http://purl.org/np/RANqKCxcsU... RANqKCxcsU

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#type type

http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement Statement

Leoni Bücken

2021-06-27T19:07:02.641Z

http://purl.org/np/RANqKCxcsU... RANqKCxcsU

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/2000/01/rdf-schema#label label

carefully consider the potential benefits and risks of naprosyn ec naprosyn anaprox anaprox ds or naprosyn suspension and other treatment options before deciding to use naprosyn ec naprosyn anaprox anaprox ds or naprosyn suspension use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see warnings naproxen as naprosyn ec naprosyn anaprox anaprox ds or naprosyn suspension is indicated for the relief of the signs and symptoms of rheumatoid arthritis for the relief of the signs and symptoms of osteoarthritis for the relief of the signs and symptoms of ankylosing spondylitis for the relief of the signs and symptoms of juvenile arthritis naproxen as naprosyn suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patient s weight naproxen as naprosyn anaprox anaprox ds and naprosyn suspension is also indicated for relief of the signs and symptoms of tendonitis for relief of the signs and symptoms of bursitis for relief of the signs and symptoms of acute gout for the management of pain for the management of primary dysmenorrhea ec naprosyn is not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen containing products see clinical pharmacology dosage and administration

Leoni Bücken

2021-06-27T19:07:02.641Z

http://purl.org/np/RANqKCxcsU... RANqKCxcsU

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#object object

http://purl.obolibrary.org/obo/DOID_2965 DOID_2965

Leoni Bücken

2021-06-27T19:07:02.641Z

http://purl.org/np/RANqKCxcsU... RANqKCxcsU

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate

https://w3id.org/biolink/vocab/treats treats

Leoni Bücken

2021-06-27T19:07:02.641Z

http://purl.org/np/RANqKCxcsU... RANqKCxcsU

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject

https://identifiers.org/drugbank:DB00788 drugbank:DB00788

Leoni Bücken

2021-06-27T19:07:02.641Z

http://purl.org/np/RANqKCxcsU... RANqKCxcsU

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/association_type association_type

https://w3id.org/biolink/vocab...OrPhenotypicFeatureAssociation ChemicalToDiseaseOrPhenotypicFeatureAssociation

Leoni Bücken

2021-06-27T19:07:02.641Z

http://purl.org/np/RANqKCxcsU... RANqKCxcsU

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/provided_by provided_by

https://w3id.org/um/NeuroDKG NeuroDKG

Leoni Bücken

2021-06-27T19:07:02.641Z

http://purl.org/np/RANqKCxcsU... RANqKCxcsU

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/relation relation

https://w3id.org/um/neurodkg/SymptomaticReliefIndication SymptomaticReliefIndication

Leoni Bücken

2021-06-27T19:07:02.641Z